Journal article
Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”
Authors
Lam CSP; Gerstein HC; Investigators OBOTA-O
Journal
Circulation, Vol. 146, No. 2, pp. e7–e7
Publisher
Wolters Kluwer
Publication Date
July 12, 2022
DOI
10.1161/circulationaha.122.060526
ISSN
0009-7322